Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Biomarker analysis for UPCI 14-118: Phase II study of pembrolizumab in combination with azacitidine in patients with refractory metastatic colorectal cancer.

(2020) Chaoyuan Kuang et al.   JOURNAL OF CLINICAL ONCOLOGY

Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status

(2020) Douglas J. Hartman et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.

(2020) Thierry Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

(2020) Kirsty Taylor et al.   Journal for ImmunoTherapy of Cancer

INTRATUMORAL ADAPTIVE IMMUNOSUPPRESSION AND TYPE 17 IMMUNITY IN MISMATCH REPAIR PROFICIENT COLORECTAL TUMORS

(2019) Nicolas J Llosa et al.   CLINICAL CANCER RESEARCH

Development of immune checkpoint therapy for cancer

(2019) Jill M. Fritz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?

(2019) François Ghiringhelli et al.   Frontiers in Immunology

Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1

(2019) Joo Sang Lee et al.   JAMA Oncology

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

(2019) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment

(2018) Ganjun Yu et al.   Cellular & Molecular Immunology

Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy

(2018) Xiaolei Li et al.   Cellular & Molecular Immunology

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

(2018) Franck Pagès et al.   LANCET

Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution

(2018) Mirjana Efremova et al.   Nature Communications

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

(2017) Nilofer S. Azad et al.   Oncotarget

A Blueprint to Advance Colorectal Cancer Immunotherapies

(2017) Dung T. Le et al.   Cancer Immunology Research

Combining Epigenetic and Immunotherapy to Combat Cancer

(2016) Katherine B. Chiappinelli et al.   CANCER RESEARCH

Regulatory T cells in cancer immunotherapy

(2016) Atsushi Tanaka et al.   CELL RESEARCH

Targeting the cancer epigenome for therapy

(2016) Peter A. Jones et al.   NATURE REVIEWS GENETICS

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

(2016) Stefani Spranger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

(2015) Robert J. Mayer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

(2015) Huili Li et al.   Oncotarget

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer

(2012) Jeffrey Chou et al.   JOURNAL OF IMMUNOTHERAPY

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

(2009) Roger M. Lyons et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficient Identification of a Novel Cancer/Testis Antigen for Immunotherapy Using Three-Step Microarray Analysis

(2008) T. Yokoe et al.   CANCER RESEARCH